search
Back to results

Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the "FITT" Device in Diabetic Foot Ulcers Patients (TriO FITT)

Primary Purpose

Diabetic Foot Ulcer

Status
Recruiting
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Study treatment administration (TriO FITT)
Physical Examination
Vital Signs
Hematology Blood Tests
Biochemistry Blood Test
Wound Digital Photography
Urine pregnancy test
Numeric Pain Rating Scale
Visual Analogue Scale
SF-36
Wounds evaluation
Sponsored by
Tri.O Medical LTD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Foot Ulcer

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Males and females 18-80 years old Chronic Diabetes Mellitus type 1 and type 2 diagnosed at least 3 years before the screening Have a single non-infected diabetic hard-to-heal wound (ulcers/foot ulcers) ≤ 0.8-40 cm2 wound area at start of treatment, for period of at least for 3 months. Wagner classification stage 1 or 2 or post-debridement stage 3. At least moderate blood perfusion into the affected limb as defined by Ankle Brachial Index (ABI) ≥0.65 Stable diabetic drugs 4 weeks before Screening Be available for the entire study period, and be able and willing to adhere to protocol requirements Provide written informed consent prior to admission into the study Exclusion Criteria: Have a glycosylated hemoglobin (HbA1c) > 10.5% Have more than one wound Have a body mass index (BMI) > 40 kg/m2 Have visible bone exposure at wound site Anemia (Hemoglobin < 9 g/dL) or White Blood Cells count > 11,000/μL or Platelets count < 100,000/μL or liver function tests > 3 times upper normal lab values or Creatinine > 3 mg/dL; any indication of malnourishment (Albumin < 3 g/dL); INR>2 or any other clinically significant blood and urinalysis tests per the physician's discretion Patients with unstable hypertension Have any clinically significant chronic or acute illness during the 4 weeks prior to admission into the study, except diabetes type 1 or 2 or during screening period Females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 2 years, not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test Participation in a clinical study or use of an investigational drug within 30 days prior to admission to this study Patients with active Gangrenous foot ulcers Active osteomyelitis (Have any signs of infection in the wound (which could be linked to raised body temperature), abscess, cellulitis, necrosis, erythema, mild drainage or known osteomyelitis) Patients with uncontrolled hyperthyroidism Patients with history of collagen diseases Patients with known allergy to ozone Anxiety, Depression, history of Mental illness or patient under Guardian Any medical condition for which the investigator deems the subject unable to participate in the study

Sites / Locations

  • Hilel Yafe Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Tri.O FITT

Arm Description

The study patients will undergo a screening period of upto 4 weeks, a traetment period of upto 12 weeks and a follow-up period of upto 12 additional weeks.

Outcomes

Primary Outcome Measures

Safety measured by number of patients who lack adverse events throughout the study.
Change in pain level between visits 1 and the last treatment evaluated by VAS & NRS scales
pain levels will be measured by the precent of change in both pain raiting scales.
Change in Quality of life (QoL) between visits 1 and the last treatment, measured by SF-36
score measures from 0 to 100, 100 being good quality of life.
Change in wound size between V1 and the last treatment
change in size (cm^2)

Secondary Outcome Measures

Full Information

First Posted
July 25, 2023
Last Updated
August 21, 2023
Sponsor
Tri.O Medical LTD
search

1. Study Identification

Unique Protocol Identification Number
NCT06003400
Brief Title
Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the "FITT" Device in Diabetic Foot Ulcers Patients
Acronym
TriO FITT
Official Title
Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the "FITT" Device in Diabetic Foot Ulcers Patients
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 29, 2023 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
January 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tri.O Medical LTD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The TriO FITT device is designed to improve the symptoms of chronic diabetic ulcers. The mechanism of action of the device optimizes and combines the administration known supproting treatments to chronic diabetic ulcers. The treatment is astimated to improve the wound conditions of acute and chronic diabetic wounds.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot Ulcer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Administration of Tri.O FITT for upto 12 weeks or until wound closure.
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tri.O FITT
Arm Type
Experimental
Arm Description
The study patients will undergo a screening period of upto 4 weeks, a traetment period of upto 12 weeks and a follow-up period of upto 12 additional weeks.
Intervention Type
Device
Intervention Name(s)
Study treatment administration (TriO FITT)
Intervention Description
Patients will be treated with the study device 2-3 times per week (determined by their wagner score) for an hour at each visit. treatment will include a combination of methods (the exact details is patented by the company and can not be elaborated).
Intervention Type
Diagnostic Test
Intervention Name(s)
Physical Examination
Intervention Description
physical examination will include an overall examination of the patient's body for any iregular findings and or physical changes from baseline.
Intervention Type
Diagnostic Test
Intervention Name(s)
Vital Signs
Intervention Description
vital signs measurement will include blood pressure, pulse and oral temperature as well as hight and weight.
Intervention Type
Diagnostic Test
Intervention Name(s)
Hematology Blood Tests
Intervention Description
complete CBC, coagulogram (PT, aPTT); D-dimer; C-reactive protein;; Ferritin; fibrinogen,
Intervention Type
Diagnostic Test
Intervention Name(s)
Biochemistry Blood Test
Intervention Description
urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides).
Intervention Type
Diagnostic Test
Intervention Name(s)
Wound Digital Photography
Intervention Description
3 photographs of the wound taken before wash, after wash and after treatment.
Intervention Type
Diagnostic Test
Intervention Name(s)
Urine pregnancy test
Intervention Description
for women with childbearing potential
Intervention Type
Other
Intervention Name(s)
Numeric Pain Rating Scale
Intervention Description
Numeric Pain Rating Scale - numeral scale from 1 to 10 measuring pain, 10 being worst pain.
Intervention Type
Other
Intervention Name(s)
Visual Analogue Scale
Intervention Description
Visual Analogue Scale - visual scale scoring 1-10 measuring pain, 10 being worst pain.
Intervention Type
Other
Intervention Name(s)
SF-36
Intervention Description
SF-36 - quality of life questionnaire scaling from 0-100, 100 being best quality of life.
Intervention Type
Diagnostic Test
Intervention Name(s)
Wounds evaluation
Intervention Description
including size measurements and visual description.
Primary Outcome Measure Information:
Title
Safety measured by number of patients who lack adverse events throughout the study.
Time Frame
0 to 28 weeks
Title
Change in pain level between visits 1 and the last treatment evaluated by VAS & NRS scales
Description
pain levels will be measured by the precent of change in both pain raiting scales.
Time Frame
0 to 28 weeks
Title
Change in Quality of life (QoL) between visits 1 and the last treatment, measured by SF-36
Description
score measures from 0 to 100, 100 being good quality of life.
Time Frame
0 to 28 weeks
Title
Change in wound size between V1 and the last treatment
Description
change in size (cm^2)
Time Frame
0 to 28 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females 18-80 years old Chronic Diabetes Mellitus type 1 and type 2 diagnosed at least 3 years before the screening Have a single non-infected diabetic hard-to-heal wound (ulcers/foot ulcers) ≤ 0.8-40 cm2 wound area at start of treatment, for period of at least for 3 months. Wagner classification stage 1 or 2 or post-debridement stage 3. At least moderate blood perfusion into the affected limb as defined by Ankle Brachial Index (ABI) ≥0.65 Stable diabetic drugs 4 weeks before Screening Be available for the entire study period, and be able and willing to adhere to protocol requirements Provide written informed consent prior to admission into the study Exclusion Criteria: Have a glycosylated hemoglobin (HbA1c) > 10.5% Have more than one wound Have a body mass index (BMI) > 40 kg/m2 Have visible bone exposure at wound site Anemia (Hemoglobin < 9 g/dL) or White Blood Cells count > 11,000/μL or Platelets count < 100,000/μL or liver function tests > 3 times upper normal lab values or Creatinine > 3 mg/dL; any indication of malnourishment (Albumin < 3 g/dL); INR>2 or any other clinically significant blood and urinalysis tests per the physician's discretion Patients with unstable hypertension Have any clinically significant chronic or acute illness during the 4 weeks prior to admission into the study, except diabetes type 1 or 2 or during screening period Females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 2 years, not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test Participation in a clinical study or use of an investigational drug within 30 days prior to admission to this study Patients with active Gangrenous foot ulcers Active osteomyelitis (Have any signs of infection in the wound (which could be linked to raised body temperature), abscess, cellulitis, necrosis, erythema, mild drainage or known osteomyelitis) Patients with uncontrolled hyperthyroidism Patients with history of collagen diseases Patients with known allergy to ozone Anxiety, Depression, history of Mental illness or patient under Guardian Any medical condition for which the investigator deems the subject unable to participate in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ronen Ben Ari
Phone
+972525605209
Email
Ronen@trio-medical.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronen Ben Ari
Organizational Affiliation
CEO
Official's Role
Study Director
Facility Information:
Facility Name
Hilel Yafe Medical Center
City
Hadera
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maxim Gurevich, Dr.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the "FITT" Device in Diabetic Foot Ulcers Patients

We'll reach out to this number within 24 hrs